Cocrystal Pharma (COCP) Stock Analysis & Winston Score

Cocrystal Pharma is a small biotechnology company that tries to develop new antiviral medicines — drugs that fight viruses. Its main focus is on creating treatments for influenza (the flu), norovirus (stomach bugs), and hepatitis C. The company uses a special scientific method called "structure-based drug design" to build drug candidates, meaning it studies the shape of viruses at a molecular level to design drugs that can block them. Cocrystal makes no product revenue yet — it is entirely in the research and development stage, which explains its deeply negative operating margin. The company is based in the United States and is very small, with a market cap near zero and no approved drugs on the market. It funds operations primarily through stock offerings, which dilutes existing shareholders over time. The biggest risk is that drug development is expensive and uncertain, and Cocrystal must successfully advance a drug candidate through clinical trials and find a partner or funding source before its cash runs out.